 |
VOOZH | about |
|
VOOZH | about |
*604050
Table of Contents
Alternative titles; symbols
HGNC Approved Gene Symbol: DLEC1
Cytogenetic location: 3p22.2 Genomic coordinates (GRCh38) : 3:38,039,208-38,124,025 (from NCBI)
The 3p22-p21.3 chromosomal segment is 1 of 3 regions on 3p that are commonly deleted in various carcinomas. By analysis of clones from 3p22-p21.3, Daigo et al. (1999) identified a novel gene that they designated DLC1 (deleted in lung cancer-1). The predicted DLC1 protein contains 1,755 amino acids. Expression of DLC1 significantly suppressed the growth of 4 different cancer cell lines. Northern blot analysis revealed that DLC1 was expressed as 6- and 8-kb mRNAs in all tissues tested, most abundantly in prostate and testis. By sequence analysis, Daigo et al. (1999) determined that the 8-kb mRNA and several other alternatively spliced DLC1 transcripts contain disrupted coding regions and are likely to encode nonfunctional proteins. RT-PCR experiments indicated that 33% of primary lung (211980), esophageal (133239), and renal cancers and cancer cell lines tested either lacked DLC1 transcripts entirely or contained increased levels of nonfunctional DLC1 mRNA. The authors concluded that aberrant transcription of DLC1 may be involved in carcinogenesis of the lung, esophagus, and kidney.
Daigo et al. (1999) determined that the DLC1 gene contains 37 exons and spans approximately 59 kb.
Daigo et al. (1999) reported that the DLEC1 gene is located between the PLC-delta-1 (PLCD1; 602142) and OXSR1 (604046) genes on 3p22-p21.3.
Daigo, Y., Nishiwaki, T., Kawasoe, T., Tamari, M., Tsuchiya, E., Nakamura, Y. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res. 59: 1966-1972, 1999. [PubMed: 10213508, related citations]
Alternative titles; symbols
HGNC Approved Gene Symbol: DLEC1
Cytogenetic location: 3p22.2 Genomic coordinates (GRCh38) : 3:38,039,208-38,124,025 (from NCBI)
The 3p22-p21.3 chromosomal segment is 1 of 3 regions on 3p that are commonly deleted in various carcinomas. By analysis of clones from 3p22-p21.3, Daigo et al. (1999) identified a novel gene that they designated DLC1 (deleted in lung cancer-1). The predicted DLC1 protein contains 1,755 amino acids. Expression of DLC1 significantly suppressed the growth of 4 different cancer cell lines. Northern blot analysis revealed that DLC1 was expressed as 6- and 8-kb mRNAs in all tissues tested, most abundantly in prostate and testis. By sequence analysis, Daigo et al. (1999) determined that the 8-kb mRNA and several other alternatively spliced DLC1 transcripts contain disrupted coding regions and are likely to encode nonfunctional proteins. RT-PCR experiments indicated that 33% of primary lung (211980), esophageal (133239), and renal cancers and cancer cell lines tested either lacked DLC1 transcripts entirely or contained increased levels of nonfunctional DLC1 mRNA. The authors concluded that aberrant transcription of DLC1 may be involved in carcinogenesis of the lung, esophagus, and kidney.
Daigo et al. (1999) determined that the DLC1 gene contains 37 exons and spans approximately 59 kb.
Daigo et al. (1999) reported that the DLEC1 gene is located between the PLC-delta-1 (PLCD1; 602142) and OXSR1 (604046) genes on 3p22-p21.3.
Daigo, Y., Nishiwaki, T., Kawasoe, T., Tamari, M., Tsuchiya, E., Nakamura, Y. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res. 59: 1966-1972, 1999. [PubMed: 10213508]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM